PMID: 6405081Mar 1, 1983Paper

Benzodiazepines: significance of kinetics for therapy

Klinische Wochenschrift
H R Ochs

Abstract

The onset and duration of action of benzodiazepines after single oral doses depend largely on absorption rate and the rate and extent of distribution. The rate and extent of accumulation during multiple dosage depend on elimination half-life and clearance. A framework is proposed for classification of benzodiazepines according to elimination half-life. Long acting benzodiazepines have half-life values usually exceeding 24 h. Drugs in this category have long-acting pharmacologically active metabolites, often desmethyldiazepam, accumulate extensively during multiple dosage, and may have impaired clearance in the elderly and those with liver disease. Intermediate and short-acting benzodiazepines have half-life values from 5-24 h and active metabolites are uncommon. Accumulation during multiple dosage is less extensive than with the long-acting group and diminishes as the half-life becomes shorter. Age and liver disease have a small influence on metabolic clearance. The half-life of ultrashort-acting benzodiazepines is less than 5 h. These drugs are essentially nonaccumulating. Pharmacokinetic classification may assist in understanding differences among benzodiazepines, but does not explain all of their clinical actions.

References

Mar 1, 1977·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Aug 1, 1977·Journal of Pharmacokinetics and Biopharmaceutics·C W AbruzzoS A Kaplan
Sep 1, 1978·Clinical Pharmacology and Therapeutics·R I ShaderM D Allen
Oct 1, 1978·Clinical Pharmacology and Therapeutics·J W KrausG R Wilkinson
Jul 1, 1979·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Mar 28, 1979·Psychopharmacology·M W Church, L C Johnson
Oct 1, 1979·Clinical Pharmacology and Therapeutics·H R OchsG Bodem
Jan 1, 1979·Psychopharmacology·M D AllenJ D Arnold
Jun 1, 1975·British Journal of Clinical Pharmacology·T GibsonD Berry
Jan 1, 1975·Clinical Pharmacology and Therapeutics·D J GreenblattJ Koch-Weser
Aug 1, 1975·Annals of Internal Medicine·D J GreenblattJ Koch-Weser
Jan 1, 1977·British Medical Journal·C M CastledenC Hallett
Jan 1, 1978·Clinical Pharmacokinetics·M MandelliS Garattini
Sep 1, 1978·Clinical Pharmacokinetics·D J GreenblattE M Sellers
Jan 1, 1979·British Journal of Clinical Pharmacology·U Klotz, P Müller-Seydlitz
May 5, 1979·British Medical Journal·I Oswald
Aug 1, 1979·Journal of Clinical Pharmacology·M D AllenR I Shader
Sep 1, 1979·European Journal of Clinical Pharmacology·M T SmithJ H Tyrer
Apr 17, 1979·European Journal of Clinical Pharmacology·L KangasE Syvälahti
Apr 1, 1978·Clinical Pharmacology and Therapeutics·M M ReidenbergJ Cheripko
May 1, 1978·British Journal of Clinical Pharmacology·D J Greenblatt, M D Allen
Sep 15, 1978·Science·A KalesJ D Kales
Nov 1, 1978·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Jan 1, 1979·Journal of Clinical Pharmacology·S M MacLeodE M Sellers
Apr 1, 1976·Annals of Internal Medicine·H J ShullS Schenker
Feb 1, 1976·Clinical Pharmacology and Therapeutics·D J GreenblattJ Koch-Weser
May 1, 1977·The American Journal of Psychiatry·D J GreenblattJ Koch-Weser
Nov 1, 1977·Journal of Clinical Pharmacology·R I ShaderJ Koch-Weser
Feb 1, 1975·The Journal of Clinical Investigation·U KlotzG R Wilkinson
Jan 18, 1980·Science·J F TallmanD W Gallager
Apr 25, 1980·Science·K M HartseF J Zorick
Jan 1, 1981·Clinical Pharmacology and Therapeutics·F S EbertsR W Vliek
Mar 1, 1981·Clinical Pharmacokinetics·D J Greenblatt
Mar 7, 1981·Lancet·P TyrerT Huggett
Aug 1, 1981·Anesthesiology·D J GreenblattP M Lauven
Mar 1, 1981·European Journal of Clinical Pharmacology·M T SmithT O Brophy
Oct 1, 1981·Journal of Pharmaceutical Sciences·M DivollR I Shader
Nov 1, 1981·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
May 1, 1980·Journal of Pharmaceutical Sciences·W GloverR Dixon
Aug 1, 1980·Clinical Pharmacology and Therapeutics·M D AllenR I Shader
Jan 1, 1981·British Journal of Clinical Pharmacology·D J GreenblattR I Shader

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

British Journal of Clinical Pharmacology
D J GreenblattJ S Harmatz
Schweizerische medizinische Wochenschrift
S Vozeh
Clinical Pharmacokinetics
D J GreenblattR I Shader
Clinical Pharmacokinetics
D J GreenblattE M Sellers
International Pharmacopsychiatry
D J GreenblattR I Shader
© 2021 Meta ULC. All rights reserved